Outlook Therapeutics Q3 2024 Adj EPS $(0.83) Beats $(1.01) Estimate
Portfolio Pulse from Benzinga Newsdesk
Outlook Therapeutics (NASDAQ:OTLK) reported a Q3 2024 adjusted EPS of $(0.83), beating the analyst consensus estimate of $(1.01) by 17.82%. This represents a 39.86% improvement over the $(1.38) loss per share from the same period last year.
August 14, 2024 | 11:06 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Outlook Therapeutics reported a Q3 2024 adjusted EPS of $(0.83), beating the analyst consensus estimate of $(1.01) by 17.82%. This is a significant improvement over the $(1.38) loss per share from the same period last year.
The better-than-expected EPS and significant year-over-year improvement are likely to positively impact the stock price in the short term as it indicates better financial performance and potential for future growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100